Veronica Sanchez Bulis sold $74k of LYEL
VP, Corporate Controller at Lyell Immunopharma, Inc.. 2,072 shares at an average of $35.80, traded Dec 24, 2025, filed Jan 6, 2026.
Score components
- +15RoleOfficer
- +8Trade size$74k at market
- +5Share of holdings soldSold 22% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -12.0%, 3m -15.4%, 6m -38.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002095702-26-000001, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 24, 2025 | SOpen-market sale Common Stock | -1,136 | $38.67 | $44k | 8,077 | Jan 6, 2026 |
| Dec 30, 2025 | SOpen-market sale Common Stock | -936 | $32.32 | $30k | 7,141 | Jan 6, 2026 |
Related signals
Other insiders at Lyell Immunopharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 20, 2026 | LYELsell Lyell Immunopharma, Inc. | Jarrad Mattieu Aguirre Chief Medical Officer | $3,642 422 shares | -2% | |
| 15Weak | LYELsell Lyell Immunopharma, Inc. | David Shook Chief Medical Officer | $6,350 500 shares | -2% | |
| 35Weak | Lyell Immunopharma, Inc. | Stephen J. Hill Chief Operating Officer | $15k 989 shares | -6% | |
| 30Weak | Lyell Immunopharma, Inc. | Gary K. Lee Chief Scientific Officer | $23k 1,457 shares | -8% | |
| 56Moderate | Lyell Immunopharma, Inc. | Lynn Seely President and CEO | $149k 9,589 shares | -13% | |
| 30Weak | Lyell Immunopharma, Inc. | Veronica Sanchez Bulis VP, Corporate Controller | $8,905 621 shares | -4% | |
| 35Weak | Lyell Immunopharma, Inc. | Stephen J. Hill Chief Operating Officer | $1,276 89 shares | -0% | |
| 30Weak | Lyell Immunopharma, Inc. | Gary K. Lee Chief Scientific Officer | $1,879 131 shares | -1% | |
| 40Moderate | Lyell Immunopharma, Inc. | Lynn Seely President and CEO | $5,593 390 shares | -1% | |
| 0Weak | Lyell Immunopharma, Inc. | Innovative Cellular Therapeutics Holdings Ltd owner | $137 10 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.